Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral T-cell lymphomas: diagnosis and management.

Claire E Dearden1, Francine M Foss

  • 1Leukemia Unit, Royal Marsden Hospital, Sutton, Surrey, UK. claire.dearden@rmh.nthames.nhs.uk

Hematology/Oncology Clinics of North America
|January 9, 2004
PubMed
Summary

Purine analogs show moderate efficacy in relapsed/refractory peripheral T-cell lymphomas. Monoclonal antibody Campath-1H demonstrates promising durable remissions, suggesting its potential as a first-line therapy for T-cell malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2026
Same author

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Blood·2025
Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2025
Same author

Weekly dosing schedule of brentuximab vedotin is well tolerated in mycosis fungoides/Sézary syndrome.

British journal of haematology·2025
Same author

An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Expert opinion on biological therapy·2025
Same author

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Peripheral T-cell lymphomas (PTCLs) are aggressive hematologic malignancies with poor response to conventional chemotherapy.
  • Existing treatments offer limited efficacy, necessitating exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review the efficacy of purine analogs and monoclonal antibody therapy in treating PTCLs.
  • To evaluate the potential of Campath-1H as a first-line treatment for T-cell prolymphocytic leukemia (T-PLL).

Main Methods:

  • Review of existing literature on purine analog efficacy (pentostatin, gemcitabine) in relapsed/refractory PTCL.
  • Analysis of clinical data for Campath-1H in T-cell malignancies, including T-PLL.
  • Discussion of monoclonal antibody mechanisms and potential role in minimal residual disease and stem cell transplantation.

Related Experiment Videos

Main Results:

  • Purine analogs achieve 25-60% response rates in relapsed/refractory PTCL with low toxicity.
  • Campath-1H demonstrates durable remissions in heavily pretreated patients and up to two-thirds of T-PLL patients.
  • Campath-1H shows superior results in T-PLL compared to other therapies, indicating potential for first-line use.

Conclusions:

  • Campath-1H shows significant promise and warrants consideration as a first-line therapy for T-PLL.
  • Monoclonal antibodies may be valuable in managing minimal residual disease and facilitating stem cell transplantation in T-cell lymphomas.
  • Further large-scale, prospective, randomized trials are needed to optimize novel therapies and combination regimens for PTCLs.